Related Experiment Video
Updated: Sep 28, 2025

Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques
Published on: June 11, 2019
Large thrombus in transit in a COVID-19 patient
Sabine Bleiziffer1, Reinhard Zabel2, Jan F Gummert1
1Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, Germany.
Insights
This case study details a COVID-19 patient who developed a large intracardiac thrombus despite anticoagulation. Surgical removal was necessary, highlighting the severe thrombotic risks associated with COVID-19.
Area of Science:
- Cardiology
- Infectious Diseases
- Hematology
Background:
- COVID-19 is associated with an increased risk of thromboembolic events.
- Critically ill COVID-19 patients often receive anticoagulation therapy.
- Direct thrombin inhibitors like Argatroban are used for anticoagulation.
Observation:
- A 48-year-old female COVID-19 patient developed a large intracardiac thrombus.
- The thrombus was diagnosed after extracorporeal membrane oxygenation (ECMO) cannula removal.
- The thrombus was surgically removed from the atria.
Findings:
- Histological analysis revealed mixed acute and chronic thrombus portions.
- The thrombus had unusual finger-like appendices.
- Despite Argatroban anticoagulation, life-threatening thrombus formation occurred.
Implications:
- This case underscores the significant risk of intracardiac thrombosis in COVID-19 patients.
- Therapeutic anticoagulation may not always prevent severe thrombotic complications in COVID-19.
- Further research into managing thrombotic risks in severe COVID-19 is warranted.
Abstract:
The course of COVID-19 patients may be complicated by thromboembolic events. We report on a 48-year-old female COVID-19 patient who underwent surgical removal of a large intracardiac thrombus. As per our centre protocol, critically ill COVID-19 patients are anticoagulated by the direct thrombin inhibitor Argatroban with close monitoring of anti-IIa activity. An intra-atrial thrombus formation fixed in a patent foramen ovale but also large mobile portions in both atria was diagnosed 4 days after weaning and removal of the jugular and femoral extracorporeal membrane oxygenation cannulas. The thrombus was removed surgically via median sternotomy and on cardiopulmonary bypass. The thrombus had a bizarre appearance with several finger-like appendices, and histological analysis revealed a mixed picture of acute and chronic thrombus portions. This case highlights the risk of life-threatening thrombus formation in COVID-19 patients despite therapeutic thrombin inhibition.
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Anticoagulant Drugs: Low-Molecular-Weight Heparins

